Premium
Psychosocial care for children receiving chimeric antigen receptor (CAR) T‐cell therapy
Author(s) -
Steineck Angela,
Wiener Lori,
Mack Jennifer W.,
Shah Nirali N.,
Summers Corinne,
Rosenberg Abby R.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28249
Subject(s) - psychosocial , chimeric antigen receptor , medicine , car t cell therapy , psychosocial support , cell therapy , refractory (planetary science) , oncology , intensive care medicine , t cell , immunology , cell , psychiatry , immune system , genetics , physics , biology , astrobiology
Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of relapsed/refractory B‐cell acute lymphoblastic leukemia (ALL). However, this new paradigm has introduced unique considerations specific to the patients receiving CAR T‐cell therapy, including prognostic uncertainty, symptom management, and psychosocial support. With increasing availability, there is a growing need for evidence‐based recommendations that address the specific psychosocial needs of the children who receive CAR T‐cell therapy and their families. To guide and standardize the psychosocial care offered for patients receiving CAR T‐cell therapy, we propose the following recommendations for addressing psychosocial support.